Suzhou Basecare Medical (HKSE:02170) Altman Z2-Score: 1.20 (As of Aug. 07, 2026) — 41% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02170 Suzhou Basecare Medical Corp Ltd HKSE:02170
70 GF Score
Price HK$1.40
GF Value HK$2.93
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Suzhou Basecare Medical Altman Z2-Score?

Suzhou Basecare Medical HKSE:02170 70 Altman Z2-Score is 1.20 as of Aug. 07, 2026, which is 41% below its 10-year median of 2.04. GuruFocus rates HKSE:02170 with a GF Score™ of 70/100 and a GF Value™ of HK$2.93 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Suzhou Basecare Medical ranks worse than 65.32% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Suzhou Basecare Medical has a Altman Z2-Score of 1.20, indicating it is in Grey Zones. This implies that Suzhou Basecare Medical is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Suzhou Basecare Medical's Altman Z2-Score or its related term are showing as below:

HKSE:02170' s Altman Z2-Score Range Over the Past 10 Years
Min: -21.71   Med: 2.04   Max: 26.06
Current: 1.2

During the past 8 years, Suzhou Basecare Medical's highest Altman Z2-Score was 26.06. The lowest was -21.71. And the median was 2.04.


Suzhou Basecare Medical  (HKSE:02170) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Suzhou Basecare Medical Altman Z2-Score Related Terms


Suzhou Basecare Medical Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Suzhou Basecare Medical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Basecare Medical Altman Z2-Score Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 26.06 12.94 4.82 2.88 1.20

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 0.00 2.88 0.00 1.20

HKSE:02170 vs ABT, SYK, MDT: Altman Z2-Score Comparison

For the Medical Devices subindustry, Suzhou Basecare Medical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's Altman Z2-Score falls into.


HKSE:02170
70GF Score
Suzhou Basecare Medical Corp Ltd HKSE:02170
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Basecare Medical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Suzhou Basecare Medical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3917+3.26*-0.7038+6.72*-0.148+1.05*1.8263
=1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was HK$1,597.9 Mil.
Total Current Assets was HK$836.1 Mil.
Total Current Liabilities was HK$210.2 Mil.
Retained Earnings was HK$-1,124.7 Mil.
Pre-Tax Income was HK$-251.0 Mil.
Interest Expense was HK$-14.5 Mil.
Total Liabilities was HK$565.4 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(836.058 - 210.22)/1597.921
=0.3917

X2=Retained Earnings/Total Assets
=-1124.695/1597.921
=-0.7038

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-250.986 - -14.488)/1597.921
=-0.148

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1032.548 - 0)/565.373
=1.8263

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Suzhou Basecare Medical has a Altman Z2-Score of 1.20 indicating it is in Grey Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 1.20 mean?
Suzhou Basecare Medical (HKSE:02170) has a Altman Z2-Score of 1.20 as of Aug. 07, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Suzhou Basecare Medical and its competitors. This is 41% below median its historical median of 2.04. According to the industry distribution chart, Suzhou Basecare Medical ranks #548 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 65.3%.
Is Suzhou Basecare Medical's Altman Z2-Score too high?
Suzhou Basecare Medical's current Altman Z2-Score of 1.20 is 41% below median its 10-year median of 2.04. The Medical Devices & Instruments industry median Altman Z2-Score is 3.46. Suzhou Basecare Medical's value of 1.20 is 65.3% below this industry median. Based on the distribution chart, Suzhou Basecare Medical ranks #548 out of 839 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #548 out of 839 companies for Altman Z2-Score. This places Suzhou Basecare Medical in the lower half of its industry. The industry median Altman Z2-Score is 3.46. Suzhou Basecare Medical's value of 1.20 is 65.3% below this benchmark. While the company's 10-year median is 2.04 vs. the industry median of 3.46, Suzhou Basecare Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.46, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Basecare Medical's current Altman Z2-Score of 1.20 is 65.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current Altman Z2-Score is 1.20, which is 41% below median its own 10-year median of 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.93, compared to a current price of HK$1.40 — trading 52.2% below its estimated fair value. The current Altman Z2-Score is 1.20, which is 41% below median its 10-year median of 2.04 and 65.3% below the Medical Devices & Instruments industry median of 3.46. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current Altman Z2-Score is 1.20 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued. The current stock price of HK$1.40 is trading 52.2% below its estimated GF Value™ of HK$2.93. GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.

Key valuation signals for HKSE:02170:

  • Altman Z2-Score: 1.20 (41% below median its 10-year median of 2.04)
  • GF Value™: HK$2.93 vs. price of HK$1.40 (52.2% below fair value)
  • GF Score™: 70/100 with 7 warning signs
  • Industry Position: 65.3% below the Medical Devices & Instruments median (#548 of 839)

No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Basecare Medical Business Description

Address No. 77 Jingu Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score

Get the complete analysis for HKSE:02170

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.40
Price
HK$2.93
GF Value